Chung A B, Fas N
Department of Medicine, Emory University, Atlanta, GA 30322, USA.
Am J Med Sci. 1998 Dec;316(6):404-7. doi: 10.1097/00000441-199812000-00010.
Herpes simplex virus (HSV) hepatitis is a rare complication of HSV infection with a high reported mortality rate in untreated patients. The authors present a case of HSV hepatitis in a 26-year-old female with focal proliferative lupus nephropathy who was status post one cycle of pulse high-dose (1 gm/ m2) cyclophosphamide. Treatment with parenteral acyclovir was successful. A meta analysis of well-documented cases of HSV hepatitis treated with acyclovir, excluding those that omit initial serum concentrations of hepatic transaminases, suggests that the early administration of parenteral acyclovir may have been instrumental in the achievement of a successful outcome, and that a patient's serum levels of hepatic transaminases at the time of treatment initiation may predict outcome. This is the first reported case of successful parenteral acyclovir treatment of HSV hepatitis in a patient with lupus nephritis who has recently undergone cyclophosphamide immunosuppression, and includes a meta analysis to examine the hypothesis that initial markers of hepatic injury may predict outcome of acyclovir treatment.
单纯疱疹病毒(HSV)肝炎是HSV感染的一种罕见并发症,据报道,未经治疗的患者死亡率很高。作者报告了一例26岁患有局灶性增殖性狼疮性肾炎的女性患者发生HSV肝炎的病例,该患者在接受了一个周期的大剂量脉冲式(1克/平方米)环磷酰胺治疗后发病。静脉注射阿昔洛韦治疗取得成功。对有充分文献记录的接受阿昔洛韦治疗的HSV肝炎病例进行的荟萃分析(不包括那些未提及初始肝转氨酶血清浓度的病例)表明,早期静脉注射阿昔洛韦可能对取得成功疗效起到了作用,而且治疗开始时患者的肝转氨酶血清水平可能预测疗效。这是首例有报道的在近期接受环磷酰胺免疫抑制治疗的狼疮性肾炎患者中成功使用静脉注射阿昔洛韦治疗HSV肝炎的病例,并且包括一项荟萃分析,以检验肝损伤初始标志物可能预测阿昔洛韦治疗疗效这一假设。